Anti-Aging HGH Carries a Five-Year Federal Penalty, Clinic Warns

August 18, 2026 – PRESSADVANTAGE –

Denver Regenerative Medicine, a Front Range peptide therapy and hormone clinic with offices in Denver, Fort Collins and Colorado Springs, is publishing patient guidance clarifying that distributing human growth hormone for anti-aging purposes is a federal offense carrying up to five years in prison.

The guidance responds to a persistent gap between what Colorado patients are offered and what federal law permits. Human growth hormone is the only prescription drug in the United States subject to a specific statutory ban on off-label distribution. Under 21 U.S.C. § 333(e), distributing HGH for any use not authorized by the Secretary of Health and Human Services is a felony, and the FDA has taken the position that writing the prescription itself constitutes distribution. Authorized uses are narrow, covering growth hormone deficiency in children and adults plus muscle wasting associated with HIV. Aging is not among them. Patients across the Denver metro, Northern Colorado and the Colorado Springs corridor nonetheless encounter HGH marketed for metabolism, muscle mass and recovery.

The clinical distinction the guidance addresses is real. Growth hormone is released by the pituitary gland in pulses, concentrated in deep sleep and following exercise, and daily output declines with age. According to the National Institutes of Health reference text Endotext, secretion falls roughly by half every seven years after early adulthood in healthy men. Growth hormone secretagogues act on that signaling pathway rather than supplying the hormone directly, producing release within a person’s own physiological ceiling instead of the sustained elevation associated with injected HGH.

The regulatory picture for those secretagogues, however, is more complicated than most clinic marketing suggests, and the guidance says so plainly. Tesamorelin, approved by the FDA in 2010 under the brand name Egrifta, is the only growth hormone-releasing analog with an approved indication in the United States, and that indication is HIV-associated lipodystrophy rather than aging. Sermorelin held FDA approval as Geref before the commercial product was discontinued. The two secretagogues most commonly marketed in the peptide sector, CJC-1295 and ipamorelin, hold no FDA approval at all. Both appear on the FDA’s published list of bulk drug substances that may present significant safety risks. The agency has documented serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction and describes the available clinical data as limited. Ipamorelin acetate has remained in category 2 of the FDA’s interim compounding policy under section 503B since September 2023, meaning the agency does not consider it eligible for compounding by outsourcing facilities.

That gap between marketing and regulatory reality is the clinic’s stated reason for issuing the guidance. Denver Regenerative Medicine sources compounded medications through United States 503A and 503B pharmacies rather than the research-chemical market, where vials are frequently labeled “not for human consumption,” and requires comprehensive blood panels before any protocol is designed and at intervals during treatment.

Colorado adults weighing growth hormone optimization — including patients who have been offered HGH cycles at anti-aging clinics along the Front Range — can review Denver Regenerative Medicine’s peptide therapy protocols, sourcing standards and physician consultation process at https://denverregenerativemedicine.com/peptide-therapy/.

This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider for personal health decisions.

About Denver Regenerative Medicine

Denver Regenerative Medicine is a regenerative medicine and hormone therapy clinic serving Colorado’s Front Range, with treatment offered at three locations. Services include stem cell therapy, platelet-rich plasma, hormone replacement therapy, testosterone therapy, peptide therapy and GLP-1 weight management. Founder Joel Cherdack, D.C., established the practice; Andrew Hong, M.D., provides interventional pain management. Denver office: 455 Sherman St # 450, Denver, CO 80203. Phone: (720) 583-1648. Web: https://denverregenerativemedicine.com/

###

For more information about Denver Regenerative Medicine | Stem Cell Therapy, HRT, Testosterone Clinic, contact the company here:

Denver Regenerative Medicine | Stem Cell Therapy, HRT, Testosterone Clinic
Dr. Joel Cherdack
+17205831648
info@denverregenerativemedicine.com
455 Sherman St #450, Denver, CO 80203, United States

Media gallery